13 completed. 13 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 13 | Completed 13 |
Follow Metastases: new trials by email Literature Review of Metastases trials Research Report on Metastases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| S-1 Versus Capecitabine in the First Line Treatment of MCC Patients. Capecitabine, Teysuno, Bevacizumab - Colorectal Cancer, Metastases | Phase 3 | Completed | Dutch Colorectal Cancer Group | 161 | 2013-12-01 | 2018-03-14 |
| QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas AMG 479, Placebo, gemcitabine - Adenocarcinoma of the Pancreas, Advanced Solid Tumors | Phase 3 | Completed | NantCell, Inc. | 800 | 2011-04-07 | 2024-07-16 |
| Trial of Vinflunine Versus Alkylating Agent in Metastatic Breast Cancer vinflunine, Alkylating agent of physician choice registered in cancer - Breast Cancer, Metastases | Phase 3 | Completed | Pierre Fabre Medicament | 594 | 2009-07-01 | 2019-09-16 |
| Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy. Xaliproden (SR57746A), Placebo, Oxaliplatin - Metastases, Colorectal Neoplasms | Phase 3 | Completed | Sanofi | 879 | 2005-12-01 | 2016-05-04 |
| MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma MDX-010 (anti-CTLA4) monoclonal antibody, MDX-1379 (gp100) Melanoma Peptide Vaccine - Melanoma, Metastases | Phase 3 | Completed | Bristol-Myers Squibb | 1783 | 2004-09-01 | 2011-07-11 |
| Breast Cancer Trial of RPR109881 Versus Capecitabine in Male or Female Patients With Advanced Breast Cancer larotaxel (RPR109881, XRP9881), capecitabine - Breast Cancer, Metastases | Phase 3 | Completed | Sanofi | 438 | 2004-04-01 | 2008-08-21 |
| Whole Brain Radiation Therapy With Oxygen, With or Without RSR13, in Women With Brain Metastases From Breast Cancer Efaproxiral, Whole Brain Radiation Therapy (WBRT), Supplemental Oxygen - Breast Cancer, Metastases | Phase 3 | Completed | Spectrum Pharmaceuticals, Inc | 368 | 2004-02-01 | 2013-05-10 |
| Evaluating Panitumumab (ABX-EGF) Plus Best Supportive Care Versus Best Supportive Care in Patients With Metastatic Colorectal Cancer Best supportive care, Panitumumab - Colorectal Cancer, Metastases | Phase 3 | Completed | Amgen | 463 | 2004-01-01 | 2022-11-07 |
| Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer Ixabepilone + Capecitabine, Capecitabine - Breast Cancer, Metastases | Phase 3 | Completed | R-Pharm | 752 | 2003-09-01 | 2020-11-02 |
| Phase III Trial of DP Followed by FOLFIRI or the Reverse Sequence in Unresectable Gastric Cancer DP, FOLFIRI - Gastric Cancer, Metastases | Phase 3 | Completed | Samsung Medical Center | 200 | 2003-05-01 | 2012-01-12 |
| A Study to Evaluate Avastin in Patients Treated in a Previous Genentech-Sponsored Cancer Study Avastin (bevacizumab) - Breast Cancer, Colorectal Cancer | Phase 3 | Completed | Genentech, Inc. | 100 | 2002-10-01 | 2014-03-26 |
| XENOX - Evaluation of the Efficacy of Xaliproden in Reducing the Neurotoxicity of the Oxaliplatin + 5-FU/LV Chemotherapy SR57746A - Metastases, Colorectal Neoplasms | Phase 3 | Completed | Sanofi | 620 | 2002-07-01 | 2006-09-13 |
| Iressa Expanded Access Program (EAP) ZD1839 (Gefitinib) - Carcinoma, Non-small-cell Lung | Phase 3 | Completed | AstraZeneca | 2000-08-01 | 2013-01-04 |
Neoplasm Metastasis (13) · Breast Neoplasms (5) · Colorectal Neoplasms (5) · Neoplasms (3) · Neurotoxicity Syndromes (2) · Paresthesia (2) · Brain Neoplasms (1) · Carcinoma (1) · Carcinoma, Non-Small-Cell Lung (1) · Endocrine Gland Neoplasms (1) · Hand-Foot Syndrome (1) · Jaundice (1) · Melanoma (1) · Pancreatic Neoplasms (1) · Rectal Neoplasms (1)
Neoplasms by Site (13) · Neoplastic Processes (13) · Pathologic Processes (13) · Pathological Conditions, Signs and Symptoms (13) · Neoplasms (10) · Digestive System Diseases (7) · Digestive System Neoplasms (7) · Skin Diseases (7) · Skin and Connective Tissue Diseases (7) · Gastrointestinal Diseases (6) · Gastrointestinal Neoplasms (6) · Breast Diseases (5) · Colonic Diseases (5) · Intestinal Diseases (5) · Intestinal Neoplasms (5)
Capecitabine (3) · Bevacizumab (2) · xaliproden (2) · Antibodies, Monoclonal (1) · Epothilones (1) · Fluorouracil (1) · Gefitinib (1) · Gemcitabine (1) · IFL protocol (1) · Ipilimumab (1) · Leucovorin (1) · Oxaliplatin (1) · Panitumumab (1) · RPR 109881A (1) · S 1 (combination) (1)
Sanofi (3) · Amgen (1) · AstraZeneca (1) · Bristol-Myers Squibb (1) · Dutch Colorectal Cancer Group (1) · Genentech, Inc. (1) · NantCell, Inc. (1) · Pierre Fabre Medicament (1) · R-Pharm (1) · Samsung Medical Center (1) · Spectrum Pharmaceuticals, Inc (1)
United Kingdom (7) · United States (7) · Argentina (6) · Brazil (6) · Canada (6) · France (6) · Germany (6) · Hungary (6) · Italy (6) · Spain (6) · Austria (4) · Belgium (4) · Chile (4) · Poland (4) · Portugal (4)
Cornelis JA Punt, Prof MD PhD (1) · John Suh, MD (1) · Karim Keddad, MD, PhD (1) · Won Ki Kang, MD (1)
PMID 30679026, PMID 31378656, PMID 36606664, PMID 17968020, PMID 18316791, PMID 20525992, PMID 21128114, PMID 21937232, PMID 22694829, PMID 23400564, PMID 23444228, PMID 23625191, PMID 23942774, PMID 24472478, PMID 25214238, PMID 25649350, PMID 25667295, PMID 26049686, PMID 26627641, PMID 26700304, PMID 28383633, PMID 29481630, PMID 29627309, PMID 30782413, PMID 34213592, PMID 37596461